Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution
– ARCALYST® (rilonacept) Q2 2024 net product revenue of $103.4 million, representing 90% year-over-year growth – – ARCALYST 2024 expected net product revenue increased to $405 - $415 million – – Abiprubart clinical development fully funded; Phase 2b …